Ovarian Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against ovarian cancer and guarantee the finest results for our customers all over the world.

Ovarian Cancer

Epithelial ovarian cancer (EOC) accounts for 140,000 deaths annually worldwide and is the leading cause of gynecologic cancer-related mortality in the United States. Approximately, 70% of EOC patients present with advanced disease, and although the majority will respond to surgery and first-line chemotherapy, most of these responses are not durable: more than 90% of suboptimal surgically debulked patients and 70% of optimally debulked patients will relapse in 18 to 24 months. The major subtypes of ovarian carcinomas include high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), low grade serous carcinoma (LGSC), and mucinous carcinoma (MC). More recently, four molecular subtypes (C1/mesenchymal, C2/immune, C4/differentiated, and C5/proliferative) have been identified in HGSC and validated by gene expression profiling, and these are associated with differential clinical outcomes.

Ovarian Cancer - Creative Biolabs

Therapeutic Vaccines for Ovarian Cancer

  • Target Antigens and Vaccine Therapy for Ovarian Cancer

CT antigens are a subclass of TAs encoded by approximately 140 genes. CT genes or gene families have been found with the following two distinguishing features: (a) mRNA expression in testis and cancer cells and (b) no or highly restricted mRNA expression in normal adult somatic cells. Among CT antigens, NY-ESO-1, initially defined by SEREX in esophageal cancer, has been analyzed extensively in several malignancies, including ovarian cancer. The antigen elicits both cellular and humoral immune responses in a high proportion of patients with advanced NY-ESO-1-expressing tumors, including ovarian cancer. Emerging evidence suggests that NY-ESO-1 and some additional CT antigens may be selectively expressed by cancer “stem cells”. Therefore, the development of strategies to target CT antigens in ovarian cancer could have potential therapeutic benefit.

  • Whole Tumor Vaccines in Ovarian Cancer

A study is testing administration of partially mature DCs pulsed with autologous tumor cell lysate to subjects with recurrent ovarian cancer in combination with immunomodulation using oral metronomic cyclophosphamide (to deplete Tregs) and bevacizumab (to disrupt the blood-tumor endothelial barrier). RNA electroporation of DCs is a convenient approach to generate a potent tumor vaccine.

  • Neoantigen Vaccines

Advances in next-generation sequencing and epitope prediction now permit the rapid identification of mutant tumor neoantigens. This has led to efforts to use these mutant tumor neoantigens for personalizing cancer immunotherapies. Indirect support for this approach comes from studies demonstrating (a) that infusion of autologous ex vivo expanded TILs can induce objective clinical responses in metastatic melanoma, and (b) the relationship between pretherapy CD8+ T cell infiltrates and response to checkpoint blockade in melanoma. Deep-sequencing technologies permit easy identification of the mutations present within the protein encoding part of the genome (the exome) of an individual tumor, allowing for prediction of potential neoantigens. Epitope presentation of neoantigens by MHC class I molecules may be predicted using previously established algorithms that analyze critical features, such as the likelihood of proteasomal processing, transport into the endoplasmic reticulum, and affinity for the relevant MHC class I alleles. In order to predict epitope abundance, gene and/or protein expression levels can also be integrated into the analysis. Based on these considerations, it becomes of interest to stimulate neoantigen-specific T cell responses in cancer patients using two possible approaches. The first is to synthesize long peptide vaccines that encode a set of predicted neoantigens. The second approach is to identify and expand preexisting neoantigen-specific T cell populations to create either bulk neoantigen-specific T cell products or TCR-engineered T cells for adoptive therapy. It is anticipated that such clinical trials will be undertaken in the near future.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the ovarian cancer vaccines. If you are interested in our services, please contact us for more details.


Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket